Comparing the Effects of Dapagliflozin and Acetazolamide Added to Standard Treatment in Adults Hospitalized with Acute Heart Failure

What this Trial Is About

Researchers are comparing the effects of two medications, dapagliflozin and acetazolamide, in adults hospitalized with acute heart failure who show signs of fluid overload. This study aims to see which drug better improves fluid removal and breathing difficulty, as well as shortens hospital stays. Both drugs will be given alongside standard loop diuretic therapy, and their safety will be monitored to detect any side effects. The goal is to gather evidence that could help improve treatment for acute heart failure. Participants will be randomly assigned to receive either dapagliflozin 10 mg once daily or acetazolamide 500 mg once daily, both taken by mouth in addition to their usual loop diuretics and care for three days. This is a double-blind study, so neither the participants nor the researchers will know which treatment is given. The study begins shortly after hospital admission and treatments are given during the initial days of hospitalization. During the study, participants will be monitored closely for changes in their breathing difficulty using a visual scale from baseline to day three. Other health assessments and safety checks will be completed to track responses and any side effects. The overall hospital stay length and kidney function will also be observed. The total participation time covers the initial hospitalization period and follow-up assessments as scheduled by the study team.

Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure